Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03773302
Other study ID # QBGJ398-301
Secondary ID 2018-004004-19
Status Terminated
Phase Phase 3
First received
Last updated
Start date December 27, 2019
Est. completion date March 2, 2023

Study information

Verified date April 2024
Source QED Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma. The purpose of the study is to evaluate the efficacy and safety of the investigational agent oral infigratinib vs standard of care chemotherapy (gemcitabine plus cisplatin) in first-line treatment of participants with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion/rearrangement. Subjects will be randomized 2:1 to receive infigratinib or gemcitabine plus cisplatin.


Recruitment information / eligibility

Status Terminated
Enrollment 48
Est. completion date March 2, 2023
Est. primary completion date March 2, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed unresectable locally advanced or metastatic cholangiocarcinoma. Participants with gallbladder cancer or ampulla of Vater carcinoma are not eligible - Have written documentation of local laboratory or central laboratory determination of a known or likely activating FGFR2 fusion/rearrangement from a sample collected before randomization - Have an archival tumor tissue sample available with sufficient tumor content for FGFR2 fusion/rearrangement molecular testing by the central laboratory. However, if an archival tumor tissue sample is not available, or does not meet requirements for central testing a newly obtained (before randomization) tumor biopsy may be submitted instead. If a prestudy written documentation of FGFR2 fusion/rearrangement in tumor tissue is available from the central laboratory, an additional tumor sample does not need to be submitted. - Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Are able to swallow and retain oral medication - Are willingness to avoid pregnancy or father children Exclusion Criteria: - Received treatment with any systemic anti-cancer therapy for unresectable locally advanced or metastatic cholangiocarcinoma, with following exceptions 1. Prior neoadjuvant or adjuvant therapy is permitted if completed > 6 months after the last dose of neoadjuvant or adjuvant therapy. 2. One cycle of gemcitabine-based chemotherapy for locally advanced or metastatic cholangiocarcinoma is permitted before randomization - History of a liver transplant - Received previously or currently is receiving treatment with a mitogen activated protein kinase kinase (MEK) or selective FGFR inhibitor - Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral infigratinib (such as, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection). - Current evidence of endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis etc. - History and/or current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, myocardium, vascular system and lung with the exception of calcified lymph nodes, minor pulmonary parenchymal calcifications, and asymptomatic coronary calcification - Current evidence of corneal or retinal disorder/keratopathy - Receiving and continued treatment or are planning to receive agents or consuming foods that are known moderate or strong inducers or inhibitors of CYP3A4 and medications which increase serum phosphorus and/or calcium concentration - Clinically significant or uncontrolled cardiac disease - Recent (= 3 months prior to first dose of study drug) transient ischemic attack or stroke - Severe hearing loss - Severe neuropathy - History of another primary malignancy within 3 years except adequately treated in-situ carcinoma of the cervix or non-melanoma skin cancer or other curatively treated malignancy that is not expected to require treatment - Pregnant or breastfeeding - Have known microsatellite instability-high (MSI-H) disease and the decision is made by the treating investigator that an alternative, non-study therapy is warranted according to standard of care. - Have any known hypersensitivity to gemcitabine, cisplatin, calcium-lowering agents, infigratinib, or their excipients - Have any contraindication to cisplatin or gemcitabine treatment according to local labeling or standard institutional practice. - Have taken any Chinese herbal medicine or Chinese patent medicine treatments with anticancer activity within 14 days of the first dose of study drug. - Have received a live vaccine within 30 days before the first dose of study drug or are planning to receive a live vaccine during participation in this study

Study Design


Intervention

Drug:
BGJ398
Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
Gemcitabine
Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
Cisplatin
Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.

Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide South Australia
Australia Monash Medical Centre Bentleigh East Victoria
Australia Chris O'Brien Lifehouse Hospital Camperdown New South Wales
Australia Blacktown Hospital Darlinghurst New South Wales
Australia Peninsula & South Eastern Haematology and Oncology Group Frankston Victoria
Australia St John of God Hospital Subiaco Subiaco Western Australia
Belgium Cliniques Universitaires Saint-Luc Bruxelles Brussels
Belgium Grand Hopital de Charleroi Charleroi
Belgium Universitair Ziekenhuis Antwerpen Edegem
Canada Cross Cancer Institute Edmonton Alberta
Canada Jewish General Hospital Montréal Quebec
Canada Ottawa Hospital Ottawa Ontario
Canada St. Josephs Health Centre Toronto Ontario
China Beijing Cancer Hospital Beijing
China Peking University People's Hospital Beijing
China Peking University Third Hospital Beijing
China Hunan Cancer Hospital Changsha
China Guangzhou First People's Hospital Guangzhou
China Hubei Cancer Hospital Hubei
China Liaoning Cancer Hospital & Institute Shenyang
China The First Affiliated Hospital, Sun Yat-sen University Zhongshan
France Hopital Henri Mondor Créteil Val-de-Marne
France Centre Georges-Francois Leclerc Dijon
France CHRU Dijon Dijon
France Hopital Claude Huriez Rue Michel Polonovski (CHRU) Lille Lille
France Groupement Hospitalier Edouard Herriot Lyon
France Hopital Nord Franche-Comte Montbéliard
France Groupe Hospitalier Archet I Et II Nice
France Hopital Cochin Paris
France Hôpital Saint Antoine Paris
France L'Institut Mutualiste Montsouris Paris
Germany Klinikum Dortmund gGmbH Dortmund
Germany University Clinic Heidelberg Heidelberg
Germany Klinikum rechts der Isar der Technischen Universität München München Bayern
Germany Universitätsklinikum Tübingen Tübingen Baden-Wurttemberg
Italy Azienda Socio Sanitaria Territoriale di Cremona (ASST) Cremona
Italy Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST Meldola
Italy ASST Grande Ospedale Metropolitano Niguarda Milano
Italy Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano
Italy Istituto Oncologico Veneto - I.R.C.C.S. Padova
Italy Policlinico Universitario Campus Biomedico Di Roma Roma
Korea, Republic of Pusan National University Hospital Pusan
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severance Hospital Yonsei University Health System Seoul
Korea, Republic of SMG - SNU Boramae Medical Center Seoul
Korea, Republic of The Catholic University of Korea, Seoul St. Mary's Hospital Seoul
Korea, Republic of Ajou University Hospital Suwon-si
Portugal Hospital Garcia de Orta Almada
Portugal Centro Hospitalar E Universitário de Coimbra EPE Coimbra
Portugal Instituto Português de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra EPE Coimbra
Portugal Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria Lisboa
Portugal Hospital CUF Descobertas Lisboa
Portugal Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. Lisbon
Portugal Hospital Beatriz Angelo Loures Lisboa
Portugal Centro Hospitalar de São João, E.P.E. Porto
Portugal Centro Hospitalar do Porto - Hospital de Santo António Porto
Portugal Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS Porto
Puerto Rico Hospital Oncologico, Puerto Rico Medical Center Rio Piedras
Spain Hospital Universitario Germans Trias i Pujol Badalona Cataluna
Spain Hospital Universitario Vall d'Hebrón - PPDS Barcelona
Spain Instituto Catalan de Oncologio ICO I'Hospitalet Barcelona Cataluna
Spain Hospital General Universitario Gregorio Maranon Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario HM Sanchinarro - CIOCC Madrid
Spain Hospital Universitario La Paz Madrid
Spain Hospital Universitario Ramon y Cajal Madrid
Spain Complejo Asistencial Universitario de Salamanca - Hospital Clinico Salamanca Castilla Y Leon
Spain Hospital Universitario Virgen Macarena Sevilla Andalucia
Spain Hospital Universitari i Politecnic La Fe de Valencia Valencia
Spain Hospital Universitario Miguel Servet Zaragoza Aragon
Taiwan National Taiwan University Hospital - YunLin Branch Huwei
Taiwan Chang Gung Memorial Hospital - Kaohsiung Kaohsiung
Taiwan China Medical University Hospital Taichung City
Taiwan Chi Mei Hospital, Liouying Tainan
Taiwan National Cheng Kung University Hospital Tainan City Tainan
Taiwan National Taiwan University Hospital Taipei
Taiwan Taipei Veterans General Hospital Taipei
Taiwan Chang Gung Memorial Hospital, Linkou Taoyuan City
Thailand Chulalongkorn University Bangkok
Thailand Ramathibodi Hospital Mahidol University Bangkok
Thailand Maharaj Nakorn Chiang Mai Chiang Mai University Chiang Mai
Thailand Songklanagarind Hospital, Prince of Songkla University Hat Yai Songkla
Thailand Srinagarind Hospital Khon Kaen
Thailand Naresuan University Phitsanulok
United Kingdom The Clatterbridge Cancer Centre NHS Foundation Trust Bebington Wirral
United Kingdom Guys Hospital London
United Kingdom The Christie NHS Foundation Trust - PPDS Manchester
United Kingdom Nottingham City Hospital Nottingham Nottinghamshire
United Kingdom Royal Marsden Hospital Sutton Surrey
United States Massachusetts General Hospital Boston Massachusetts
United States Charleston Oncology Charleston South Carolina
United States Levine Cancer Institute - Charlotte Charlotte North Carolina
United States Northwestern Memorial Hospital Chicago Illinois
United States University of Cincinnati Medical Center Cincinnati Ohio
United States Ohio State University Comprehensive Cancer Center Columbus Ohio
United States Parkland Health and Hospital System Dallas Texas
United States University of Texas Southwestern Medical Center Dallas Texas
United States Barbara Ann Karmanos Cancer Institute - Lawrence and Idell Weisberg Cancer Treatment Center Detroit Michigan
United States Frederick Regional Healthcare Systems/James M. Stockman Cancer Institute Frederick Maryland
United States St. Joseph Heritage Healthcare Fullerton California
United States Banner MD Anderson Cancer Center Gilbert Arizona
United States Cancer and Hematology Centers of Western Michigan Grand Rapids Michigan
United States Baylor College of Medicine Houston Texas
United States University of Texas MD Anderson Cancer Center Houston Texas
United States University of Arkansas for Medical Sciences Little Rock Arkansas
United States University of California Los Angeles Los Angeles California
United States USC Norris Cancer Center Los Angeles California
United States University Medical Center - New Orleans New Orleans Louisiana
United States Memorial Sloan Kettering Cancer Center New York New York
United States NYU Langone Medical Center New York New York
United States Florida Hospital Medical Group Orlando Florida
United States UF Health Cancer Center at Orlando Health Orlando Florida
United States William Beaumont Hospital Royal Oak Michigan
United States University of Arizona Tucson Arizona

Sponsors (2)

Lead Sponsor Collaborator
QED Therapeutics, Inc. Helsinn Healthcare SA

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Canada,  China,  France,  Germany,  Italy,  Korea, Republic of,  Portugal,  Puerto Rico,  Spain,  Taiwan,  Thailand,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free Survival (Central Imaging Assessment) Defined as the time from randomization until date of disease progression by blinded independent central imaging assessment (Response Evaluation Criteria in Solid Tumors [RECIST] v. 1.1) or death, whichever occurs first. From the time of randomization to end of treatment due to confirmed disease progression or death. Note: PFS is an event driven endpoint. Subjects without confirmed disease progression at the end of study were censored at their last valid tumor assessment.
Secondary Overall Survival (OS) in Participants Treated With Infigratinib Versus Gemcitabine With Cisplatin OS by investigator assessment, defined as time from date of randomization until death due to any cause From the time of randomization to time of death. Note: OS is an event driven endpoint. Subjects who had not died (no record of death) or were lost to follow-up were censored at the date of last known to be alive.
Secondary Investigator Assessed Progression Free Survival in Participants Treated With Infigratinib Compared to Gemcitabine and Cisplatin Defined as the time from randomization until date of disease progression by site investigator (RECIST v1.1) or death, whichever occurs first. From the time of randomization to end of treatment due to confirmed disease progression or death. Note: PFS is an event driven endpoint. Subjects without confirmed disease progression at the end of study were censored at their last valid tumor assessment.
Secondary Overall Response Rate (ORR) Determined by Blinded Independent Central (BICR) and Investigator Assessment ORR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR) or confirmed complete response (CR) as assessed by BICR and the investigator according to RECIST v1.1 among patients with measurable disease at baseline From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Secondary Best Overall Response (BOR) Determined by Blinded Independent Central Assessment and the Investigator. BOR was defined as the best response a subject ever achieved after study treatment prior to crossover and any subsequent anticancer therapy, complete response (CR) and partial response (PR) were claimed only if the criteria for each were met at a subsequent time point at least 4 weeks apart. In the case of stable disease (SD), measurements must have met the SD criteria at least once post-baseline no less than 6 weeks from the randomization date. From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Secondary Duration of Response (DOR) Determined by Blinded Independent Central Assessment and the Investigator. DOR is defined as the time from initiation of confirmed partial response (PR) or confirmed complete response (CR) to the time of confirmed progressive disease (PD) or death. If subjects do not reach PD or death before crossover, the DOR is censored at the last valid tumor assessment before crossover. From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Secondary Disease Control Rate (DCR=PR+CR+SD) Determined by Blinded Independent Central Assessment and the Investigator. DCR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR), confirmed complete response (CR) or stable disease (SD) or non-CR/non-PD before crossover. From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Secondary Number of Participants With Adverse Events (AEs) Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period From baseline to last dose date of study treatment + 30 days (an average of 7.5 months for the infigratinib arm and 5 months for the gemcitabine + cisplatin arm).
Secondary Number of Participants With Serious Adverse Events (SAEs) Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period From baseline to last dose date of study treatment + 30 days (an average of 7.5 months for the infigratinib arm and 5 months for the gemcitabine + cisplatin arm).
See also
  Status Clinical Trial Phase
Recruiting NCT05823311 - Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma Phase 3
Not yet recruiting NCT06439485 - Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion Phase 2
Recruiting NCT06420349 - NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma Phase 1
Recruiting NCT05727176 - Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement Phase 2
Recruiting NCT05791448 - AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease Phase 1
Active, not recruiting NCT04093362 - Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements Phase 3
Recruiting NCT03996408 - Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma Phase 1/Phase 2
Terminated NCT02982720 - Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron Phase 2
Terminated NCT02150967 - A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Phase 2
Recruiting NCT03982680 - Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma Phase 2
Recruiting NCT05532059 - Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma Phase 2
Terminated NCT04088188 - Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma Phase 1
Completed NCT02989857 - Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Phase 3
Recruiting NCT05805956 - IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 Phase 1/Phase 2
Approved for marketing NCT04507503 - Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements